Investigational Janus kinase inhibitors

Bibliography

• Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6(4):6372-5
   Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97
   PubMed Web of Science ®Google Scholar
• Wilks AF, Harpur AG, Kurban RR, et al. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991;11:2057-65
   PubMed Web of Science ®Google Scholar
• Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science 1995;270:800-2
   PubMed Web of Science ®Google Scholar
• Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000;13:561-71
   PubMed Web of Science ®Google Scholar
• Anand S, Huntly B. Disordered signaling in myeloproliferative neoplasms. Hematol Oncol Clin North Am 2012;26:1017-35
   PubMed Web of Science ®Google Scholar
• Feener EP, Rosario F, Dunn SL. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 2004;24:4968-78
   PubMed Web of Science ®Google Scholar
• Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002;277:47954-63
   PubMed Web of Science ®Google Scholar
• Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274-81
   PubMed Web of Science ®Google Scholar
• Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108:1652-60
   PubMed Web of Science ®Google Scholar
• Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006;1:e18
   PubMed Web of Science ®Google Scholar
• Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006;66:11156-65
   PubMed Web of Science ®Google Scholar
• Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008;111:3931-40
   PubMed Web of Science ®Google Scholar
• Anand S, Stedham F, Gudgin E, et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood 2011;118:1610-21
   PubMed Web of Science ®Google Scholar
• Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6
   PubMed Web of Science ®Google Scholar
• Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010;363:1189-90
   PubMed Web of Science ®Google Scholar
• Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116:988-92
   PubMed Web of Science ®Google Scholar
• Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-92
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-8
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72
   PubMed Web of Science ®Google Scholar
• Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 2008;112:1628-37
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006;108:3548-55
   PubMed Web of Science ®Google Scholar
• Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007;110:375-9
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
   PubMed Web of Science ®Google Scholar
• Talpaz M, Paquette R, Afrin L, et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 x 109/L): a comparison to patients with normal or high starting platelet counts. ASH Annl Meet Abstr 2012;120:176
   Google Scholar
• Harrison CN, Gisslinger H, Miller CB, et al. Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 x 109/L and 99 x 109/L. ASH Annl Meet Abstr 2012;120:177
   Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) refractory or intolerant to Hydroxyurea (HU). ASH Annl Meet Abstr 2010;116:313
   Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. Long-term efficacy and safety results from a phase II study of ruxolitinib in patients with polycythemia vera. ASH Annl MeetAbstr 2012;120:804
   Google Scholar
• Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009;114:5024-33
   PubMed Web of Science ®Google Scholar
• Baffert F, Evrot E, Ebel N, et al. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease. Annl Meet Abstr 2011;118:798
   Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-503
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian HM, Estrov Z, et al. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy. Annl Meet Abstr 2011;118-793
   Google Scholar
• Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011;365:1455-7
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188-91
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Long-Term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Annl Meet Abstr 2012;120:800
   Google Scholar
• Cervantes F, Kiladjian J-J, Niederwieser D, et al. Long-term safety, efficacy, and survival findings from comfort-II, a phase 3 study comparing ruxolitinib with Best Available Therapy (BAT) for the treatment of Myelofibrosis (MF). Annl Meet Abstr 2012;120:801
   Google Scholar
• Mesa RA, Gotlib J, Kantarjian HM, et al. Clinical benefits of ruxolitinib therapy in myelofibrosis patients with varying degrees of splenomegaly and symptoms. Annl Meet Abstr 2012;120:1727
   Google Scholar
• Mesa RA, Verstovsek S, Gupta V, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I. Annl Meet Abstr 2012;120:1733
   Google Scholar
• Vannucchi AM, Passamonti F, Al-Ali HK, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in Comfort-II, a phase 3 study comparing the safety and efficacy of ruxolitinib with Best Available Therapy (BAT). Annl Meet Abstr 2012;120:802
   Google Scholar
• Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-63
   PubMed Web of Science ®Google Scholar
• McMullin MF, Harrison CN, Niederwieser D, et al. The use of Erythropoietic-Stimulating Agents (ESAs) with ruxolitinib in patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF). Annl Meet Abstr 2012;120:2838
   Google Scholar
• Verstovsek S, Kiladjian J-J, Mesa RA, et al. Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from ruxolitinib clinical trials. Annl Meet Abstr 2012;120:2847
   Google Scholar
• Barosi G, Agarwal M, Zweegman S, et al. An individual patient supply program for ruxolitinib for the treatment of patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF). Annl Meet Abstr 2012;120:2844
   Google Scholar
• Andreoli A, Rey J, Dauriac C, et al. Ruxolitinib therapy in myelofibrosis: analysis of 241 patients treated in compassionate use (French "ATU" program) by the French Intergroup of Myeloproliferative Neoplasms (FIM). Annl Meet Abstr 2012;120:2841
   Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-24
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-72
   PubMed Web of Science ®Google Scholar
• Choong ML, Pecquet C, Tai SJ, et al. Combination treatment with JAK2 and PI3K inhibitors in myeloproliferative neoplasms. Annl Meet Abstr 2012;120-80
   Google Scholar
• Vannucchi AM, Bartalucci N, Bogani C, et al. Combined inhibition of JAK2 and mTOR signaling results in enhanced efficacy in in-vitro and preclinical mouse models of JAK2V617F-driven myeloproliferative disease. Annl Meet Abstr 2012;120:708
   Google Scholar
• Lasho TL, Tefferi A, Hood JD, et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008;22:1790-2
   PubMed Web of Science ®Google Scholar
• Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-96
   PubMed Web of Science ®Google Scholar
• Talpaz M, Jamieson C, Gabrail NY, et al. A phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or High-risk primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF. Annl Meet Abstr 2012;120:2837
   Google Scholar
• Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76
   PubMed Web of Science ®Google Scholar
• Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008.111:5663-71
   Google Scholar
• Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-6
   PubMed Web of Science ®Google Scholar
• Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011;25:1751-9
   PubMed Web of Science ®Google Scholar
• < >Verstovsek S, Odenike O, Scott B, et al. Phase I Dose-Escalation trial of SB1518, a Novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Annl Meet Abstr 2009;114:3905
   Google Scholar
• Seymour J, To B, Goh A, et al. First report of the phase I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis (abstract 1144). Haematologica 2010;95:472
   Web of Science ®Google Scholar
• Seymour J, Scott B, Robert A, et al. Long-term safety and efficacy analysis of the two phase 1 studies of SB1518, a novel oral JAK2 inhibitor, in patients with advanced myeloid malignancies (abstract 0907). Haematologica 2011;96:378
   Google Scholar
• Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of pacritinib (sb1518), a novel oral jak2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Annl Meet Abstr 2011;118:282
   Google Scholar
• Pardanani A, Lasho T, Smith G, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009;23:1441-5
   PubMed Web of Science ®Google Scholar
• Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232-40
   PubMed Web of Science ®Google Scholar
• Pardanani A, George G, Lasho T, et al. A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. ASH Annl Meet Abstr 2010;116:460
   Google Scholar
• Pardanani A, Gotlib J, Gupta V, et al. An expanded multicenter phase I/II study of CYT387, a JAK- 1/2 inhibitor for the treatment of myelofibrosis. ASH Annl MeetAbstr 2011;118:3849
   Google Scholar
• Pardanani A, Gotlib J, Gupta V, et al. Phase I/II study of CYT387, a JAK1/JAK2 inhibitor for the treatment of myelofibrosis. ASH Annl Meet Abstr 2012;120:178
   Google Scholar
• Verstovsek S, Pardanani A, Shah N, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. Annl Meet Abstr 2007;110:553
   Google Scholar
• Shah NP, Olszynski P, Sokol L, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Annl Meet Abstr 2008;112:98
   Google Scholar
• Paquette R, Sokol L, Shah NP, et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Annl Meet Abstr 2008;112:2810
   Google Scholar
• Ma L, Zhao B, Walgren R, et al. Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy Models. Annl Meet Abstr 2010;116:4087
   Google Scholar
• Verstovsek S, Mesa RA, Rhoades SK, et al. Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET). Annl Meet Abstr 2011;118:2814
   Google Scholar
• Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 2012;26:280-8
   PubMed Web of Science ®Google Scholar
• Nakaya Y, Shide K, Niwa T, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J 2011;1:e29
   PubMed Web of Science ®Google Scholar
• Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-97
   PubMed Web of Science ®Google Scholar
• Benjamini O, Jain P, Estrov Z, et al. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood 2012;120(13):2768-9
   PubMed Web of Science ®Google Scholar
• Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest 2012;122(11):3888-99
   PubMed Web of Science ®Google Scholar
• Wang X, Tripodi J, Novak J, et al. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Annl Meet Abstr 2012;120:1752
   Google Scholar
• Deshpande A, Reddy MM, Schade GO, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012;26:708-15
   PubMed Web of Science ®Google Scholar
• Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118:1208-15
   PubMed Web of Science ®Google Scholar
• Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155-9
   PubMed Web of Science ®Google Scholar
• Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012;209:259-73
   PubMed Web of Science ®Google Scholar
• Kapuria V, Levitzki A, ornmann G, et al. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cell Signal 2011;23:2076-85
   PubMedGoogle Scholar